Annotation of human cancers with EGFR signaling–associated protein complexes using proximity ligation assays

Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer

(2014) Lanxi Song et al.   Journal of Thoracic Oncology

Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer

(2014) L. Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution

(2014) S. Misale et al.   Cancer Discovery

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

(2014) M. Hidalgo et al.   Cancer Discovery

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012

(2013) Fred R. Hirsch et al.   Journal of Thoracic Oncology

Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: Re-analysis of the SATURN study

(2013) Julien Mazières et al.   LUNG CANCER

Parallel Visualization of Multiple Protein Complexes in Individual Cells in Tumor Tissue

(2013) Karl-Johan Leuchowius et al.   MOLECULAR & CELLULAR PROTEOMICS

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms

(2013) J. Li et al.   Molecular Systems Biology

The quest to overcome resistance to EGFR-targeted therapies in cancer

(2013) Curtis R Chong et al.   NATURE MEDICINE

Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer

(2013) M. H. Cohen et al.   ONCOLOGIST

Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance

(2013) C. Boeckx et al.   ONCOLOGIST

Protein Phosphorylation Profiling Using an In Situ Proximity Ligation Assay: Phosphorylation of AURKA-Elicited EGFR-Thr654 and EGFR-Ser1046 in Lung Cancer Cells

(2013) Tzu-Chi Chen et al.   PLoS One

Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas

(2013) Jenny M. Kreahling et al.   PLoS One

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

(2012) P. R. Gavine et al.   CANCER RESEARCH

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK-Positive Non-Small Cell Lung Cancer

(2012) J. Tanizaki et al.   CLINICAL CANCER RESEARCH

In Situ Analysis of Mutant EGFRs Prevalent in Glioblastoma Multiforme Reveals Aberrant Dimerization, Activation, and Differential Response to Anti-EGFR Targeted Therapy

(2012) A. S. Gajadhar et al.   MOLECULAR CANCER RESEARCH

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth

(2012) Fred Harbinski et al.   Cancer Discovery

Standardization of Epidermal Growth Factor Receptor (EGFR) Measurement by Quantitative Immunofluorescence and Impact on Antibody-Based Mutation Detection in Non–Small Cell Lung Cancer

(2011) Anastasios Dimou et al.   AMERICAN JOURNAL OF PATHOLOGY

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

(2011) J. Qi et al.   CANCER RESEARCH

EGFR Protein Expression in Non-Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor--A Novel Antibody for Immunohistochemistry or AQUA Technology

(2011) C. Mascaux et al.   CLINICAL CANCER RESEARCH

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance

(2011) Rebekka Krumbach et al.   EUROPEAN JOURNAL OF CANCER

EGFR in melanoma: clinical significance and potential therapeutic target

(2011) Barbara Boone et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Protein Pathway Activation Mapping of Brain Metastasis from Lung and Breast Cancers Reveals Organ Type Specific Drug Target Activation

(2011) Giuseppina Improta et al.   JOURNAL OF PROTEOME RESEARCH

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

(2011) Robert Pirker et al.   LANCET ONCOLOGY

Phosphorylation of EGFR measured with in situ proximity ligation assay: Relationship to EGFR protein level and gene dosage in cervical cancer

(2011) Cathinka Halle et al.   RADIOTHERAPY AND ONCOLOGY

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma

(2010) C. Ferté et al.   ANNALS OF ONCOLOGY

Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck

(2010) Mark E. Sharafinski et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

(2008) Chang-Qi Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY